Answers are grounded in this paper and cite their sources.
Multiple myeloma, plasma cell leukemia, autologous stem cell transplantation Primary plasma cell leukemia (pPCL) is defined as the presence of 5% or more circulating plasma cells on manual white blood cell differential count in newly diagnosed patients who meet the diagnostic criteria of multiple myeloma (MM) as defined by the consensus of the International Myeloma Working Group (IMWG).1,2It is important to note that the new cutoff point (>=5% circulating plasma cells) was based on a recent change of the previous definition which was based on a higher cutoff (>=20% circulating plasma cells).1 Plasma cell leukemia is considered under the category of high-risk MM and more appropriately, under the category of ultra-high-risk MM.3 Secondary plasma cell leukemia can be diagnosed using the same cut-off, but in patients with previous diagnosis of MM at time of relapse or refractory disease.Reviewing peripheral blood smear in all patients with newly diagnosed MM is important to diagnose pPCL or consider obtaining peripheral blood flow cytometry to better quantify the percentage of circulating plasma cells.Plasma cells can be identified by their eccentric nucleus, perinuclear halo, and basophilic cytoplasm.(Figure .1)Malignant plasma cells are clonal which means that their cytoplasm contains either kappa or lambda light chains, but not both.
No takes yet. Share an insight, caveat, or question.
Samer Al Hadidi (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: